SELUTION SLR PTCA Drug Eluting Balloon

The SELUTION SLR Drug Eluting Balloon (DEB) is the latest generation of drug-eluting balloon technology designed to Go Beyond Metal and deliver consistent and predictable drug release as best-in-class drug-eluting stents.

The New Paradigm for Coronary Interventions

Breakthrough technology to deliver sustained limus release up to 90 days.

CELL ADHERENT TECHNOLOGY

CELL ADHERENT TECHNOLOGY (CAT)™ facilitates drug uptake and retention, in the tissue, with a minimal drug loss during the procedure while providing excellent deliverability.

MICRORESERVOIRS

MicroReservoirs achieve a consistent and predictable drug release, at a therapeutic level, comparable to the latest generation drug-eluting stent technology

SIZE MATRIX

SELUTION SLR DEB offers a broader portfolio to extend treatment options for coronary artery disease

The SELUTION DeNovo Study*

A prospective randomized, multi-center, international, single-blind clinical trial comparing the SELUTION SLR DEB Strategy Versus Drug-Eluting Stent (DES) Strategy. 

  • Landmark randomized trial for coronary de-novo lesions, all-comers enrollment
  • Designed to evaluate non-inferiority at 1 and 5 years and possible superiority at 5 years
  • Primary Endpoints: Target Vessel Failure at 1 year and 5 years 

*Current enrollment >80% out of a total of 3326 patients (as of 30.04.2024)

SELUTION SLR DEB Cases

Complex PCI: SELUTION SLR™ DEB in long and calcified lesions

Learn More

Dr. Eccleshall, Norfolk & Norwich University Hopsitals, NHS Foundation Trust, United Kingdom

Going Beyond Metal with Drug-Eluting Balloons (DEB), an appealing and gradual process

Prof. Cuculi, Heart Centre, Lucerne, Switzerland

Towards a new era with less metal in patients' coronary arteries

Dr. Rissanen, North Karelia Central Hospital, Joensuu, Finland

Vessel preparation as the key success factor

Dr. Neylon, Jacques Cartier Private Hospital, Massy, France

Keeping bifurcations as simple as possible with less metal

:

Dr. Mashayekhi, Heartcenter Lahr, Germany

Reducing stent length in CTO with a hybrid approach

Customer Service and Ordering Information

For country-specific contact details, please see this page.